Explore the scientific journey from considering KRAS 'undruggable' to developing innovative therapies that are now extending patients' lives.
Discover how SMAPs (Small Molecule Activators of PP2A) can disarm KRAS by awakening the dormant tumor suppressor PP2A in KRAS-driven cancers.